Recurrent allergic vulvovaginitis

Treatment with Candida albicans allergen immunotherapy

Desirée Rigg, Michael Miller, W. James Metzger

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Recurrent vaginal candidiasis is a difficult problem for many women who do not respond to the usual antifungal agents. Normally these women have recurrent disease for many years before they are referred for evaluation of local vaginal hypersensitivity. We evaluated 18 women with recurrent vulvovaginal candidiasis that was unresponsive to all other modalities of therapy and who were skin-test positive to Candida albicans with a positive prick test or intradermal skin test. Three patients had late-phase skin test reactions only. Of the 18 study participants, 16 responded with significant improvement in the mean incidence of episodes of vaginitis per year from 17.2 ± 2.0 to 4.3 ± 1.8 (p < 0.0004). Overall, there was approximately 79% improvement in these patients. More than half the women were also atopic but were not first seen with these allergic symptoms. These data suggest that certain women who have chronic vaginal candidiasis may have a local hypersensitivity response to Candida that may improve with allergy immunotherapy with C. albicans extract. A double-blind, placebo-controlled trial in a homogeneous group of women with standardized extract is needed to establish this as a recommended form of therapy in this subgroup of patients.

Original languageEnglish (US)
Pages (from-to)332-336
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume162
Issue number2
DOIs
StatePublished - Jan 1 1990

Fingerprint

Vulvovaginitis
Immunologic Desensitization
Candida albicans
Skin Tests
Hypersensitivity
Candidiasis
Therapeutics
Vulvovaginal Candidiasis
Intradermal Tests
Vaginitis
Antifungal Agents
Candida
Immunotherapy
Placebos
Incidence

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Recurrent allergic vulvovaginitis : Treatment with Candida albicans allergen immunotherapy. / Rigg, Desirée; Miller, Michael; Metzger, W. James.

In: American Journal of Obstetrics and Gynecology, Vol. 162, No. 2, 01.01.1990, p. 332-336.

Research output: Contribution to journalArticle

@article{83d8f2f6b27f48eb8cb5a9bfb164483c,
title = "Recurrent allergic vulvovaginitis: Treatment with Candida albicans allergen immunotherapy",
abstract = "Recurrent vaginal candidiasis is a difficult problem for many women who do not respond to the usual antifungal agents. Normally these women have recurrent disease for many years before they are referred for evaluation of local vaginal hypersensitivity. We evaluated 18 women with recurrent vulvovaginal candidiasis that was unresponsive to all other modalities of therapy and who were skin-test positive to Candida albicans with a positive prick test or intradermal skin test. Three patients had late-phase skin test reactions only. Of the 18 study participants, 16 responded with significant improvement in the mean incidence of episodes of vaginitis per year from 17.2 ± 2.0 to 4.3 ± 1.8 (p < 0.0004). Overall, there was approximately 79{\%} improvement in these patients. More than half the women were also atopic but were not first seen with these allergic symptoms. These data suggest that certain women who have chronic vaginal candidiasis may have a local hypersensitivity response to Candida that may improve with allergy immunotherapy with C. albicans extract. A double-blind, placebo-controlled trial in a homogeneous group of women with standardized extract is needed to establish this as a recommended form of therapy in this subgroup of patients.",
author = "Desir{\'e}e Rigg and Michael Miller and Metzger, {W. James}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0002-9378(90)90380-P",
language = "English (US)",
volume = "162",
pages = "332--336",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Recurrent allergic vulvovaginitis

T2 - Treatment with Candida albicans allergen immunotherapy

AU - Rigg, Desirée

AU - Miller, Michael

AU - Metzger, W. James

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Recurrent vaginal candidiasis is a difficult problem for many women who do not respond to the usual antifungal agents. Normally these women have recurrent disease for many years before they are referred for evaluation of local vaginal hypersensitivity. We evaluated 18 women with recurrent vulvovaginal candidiasis that was unresponsive to all other modalities of therapy and who were skin-test positive to Candida albicans with a positive prick test or intradermal skin test. Three patients had late-phase skin test reactions only. Of the 18 study participants, 16 responded with significant improvement in the mean incidence of episodes of vaginitis per year from 17.2 ± 2.0 to 4.3 ± 1.8 (p < 0.0004). Overall, there was approximately 79% improvement in these patients. More than half the women were also atopic but were not first seen with these allergic symptoms. These data suggest that certain women who have chronic vaginal candidiasis may have a local hypersensitivity response to Candida that may improve with allergy immunotherapy with C. albicans extract. A double-blind, placebo-controlled trial in a homogeneous group of women with standardized extract is needed to establish this as a recommended form of therapy in this subgroup of patients.

AB - Recurrent vaginal candidiasis is a difficult problem for many women who do not respond to the usual antifungal agents. Normally these women have recurrent disease for many years before they are referred for evaluation of local vaginal hypersensitivity. We evaluated 18 women with recurrent vulvovaginal candidiasis that was unresponsive to all other modalities of therapy and who were skin-test positive to Candida albicans with a positive prick test or intradermal skin test. Three patients had late-phase skin test reactions only. Of the 18 study participants, 16 responded with significant improvement in the mean incidence of episodes of vaginitis per year from 17.2 ± 2.0 to 4.3 ± 1.8 (p < 0.0004). Overall, there was approximately 79% improvement in these patients. More than half the women were also atopic but were not first seen with these allergic symptoms. These data suggest that certain women who have chronic vaginal candidiasis may have a local hypersensitivity response to Candida that may improve with allergy immunotherapy with C. albicans extract. A double-blind, placebo-controlled trial in a homogeneous group of women with standardized extract is needed to establish this as a recommended form of therapy in this subgroup of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025019585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025019585&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(90)90380-P

DO - 10.1016/0002-9378(90)90380-P

M3 - Article

VL - 162

SP - 332

EP - 336

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -